Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis.

Annals of neurology·2026
Same author

Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimod.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Inebilizumab: Pediatric Case Series in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.

Pediatric neurology·2025
Same author

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial.

EBioMedicine·2025
Same author

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.

Journal of neurology·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025

Related Experiment Video

Updated: Feb 18, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K

Pediatric Multiple Sclerosis: From Recognition to Practical Clinical Management.

Cynthia X Wang1, Benjamin M Greenberg1

  • 1Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8806, USA.

Neurologic Clinics
|November 22, 2017
PubMed
Summary

Pediatric multiple sclerosis (MS) parallels adult MS but presents unique challenges. Early risk factor exposure and developmental considerations complicate diagnosis and treatment for children with this rare neurologic disease.

Keywords:
ChildrenDemyelinationDiagnosisMultiple sclerosisTreatment

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K

Related Experiment Videos

Last Updated: Feb 18, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Pediatric multiple sclerosis (MS) is a rare neurological disorder.
  • MS pathogenesis risk factors may be encountered in childhood.
  • Pediatric MS presents unique diagnostic and therapeutic challenges compared to adult-onset MS.

Purpose of the Study:

  • To highlight the parallels and divergences of pediatric MS from adult MS.
  • To discuss the complexities in diagnosing MS in children.
  • To address the challenges in managing pediatric MS with disease-modifying therapies.

Main Methods:

  • Review of existing literature on pediatric multiple sclerosis.
  • Analysis of diagnostic criteria and differential diagnoses for pediatric MS.
  • Examination of current therapeutic approaches and research gaps for pediatric MS.

Main Results:

  • Pediatric MS shares similarities with adult MS but has distinct features.
  • Diagnosis can be difficult due to atypical presentations in children.
  • Limited rigorous studies exist for disease-modifying therapies in pediatric MS.

Conclusions:

  • Pediatric MS requires specialized diagnostic and management strategies.
  • Further research is crucial for understanding MS pathogenesis in developing systems.
  • Developing safe and effective treatments for pediatric MS is a critical unmet need.